Compare ARKO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARKO | PRTA |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.4M | 495.8M |
| IPO Year | N/A | N/A |
| Metric | ARKO | PRTA |
|---|---|---|
| Price | $4.65 | $9.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $7.50 | ★ $18.86 |
| AVG Volume (30 Days) | 401.6K | ★ 787.9K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,887,822,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | $42.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $4.32 |
| 52 Week High | $7.84 | $16.67 |
| Indicator | ARKO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 42.93 |
| Support Level | $4.58 | $9.23 |
| Resistance Level | $5.35 | $9.88 |
| Average True Range (ATR) | 0.18 | 0.51 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 9.80 | 19.51 |
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.